TransMedics Group, Inc. (TMDX) has a consensus analyst rating of Buy, based on 12 analysts covering the stock. Of those, 9 recommend buying, 3 recommend holding, and 0 recommend selling.
The analyst consensus price target for TMDX is $146.80, representing a +26.9% upside from the current price of $115.68. Price targets range from a low of $135.00 to a high of $166.00.
